Introduction
Current numbers of hypertension cases are estimated to be ∼1 billion worldwide due to increased sedentary behaviour and widespread adoption of Western diets [1] . A meta-analysis of "Dietary Approaches to Stop Hypertension" (DASH) diets suggested that effective adherence could lead to a reduction in the risk of cardiovascular disease by 20% [2] . To date, dietary interventions have achieved only modest reductions in systolic blood pressure (SBP). To improve upon the relatively weak hypotensive actions of peptides currently presented in foodstuffs, use of purified bioactive molecules could be more effective if administered in higher doses in optimised oral formulations [3] . Bioactive di-and tri-peptides are cleaved from food-derived proteins and polypeptides by intestinal peptidases and several seem to possess anti-inflammatory [4] , anti-oxidative [5] and anti-hypertensive [6, 7] characteristics. Antihypertensive tripeptides discovered in food include Ile-Pro-Pro (IPP) (molecular weight, MW 325 Da) and Leu-Lys-Pro (LKP) (MW 389 Da). At least part of the blood-pressure lowering mechanism of action of IPP is thought to be due to competitive inhibition of angiotensin-converting enzyme (ACE), thereby preventing conversion of angiotensin I to the potent vasoconstrictor, angiotensin II [8] . This is a similar mechanism of action to the oral small molecule antihypertensive ACE inhibitors, captopril and enalaprilat [9] .
IPP and LKP are present in hydrolysates of milk β-casein and fish/ chicken muscle respectively. In the Spontaneously Hypertensive Rat (SHR) model blood pressure was reduced by oral administration of IPP [10, 11] . In particular, IPP has been tested as a potential hypotensive agent in human studies as a component of milk [12] , yogurt [13] , cheese [14] , dairy spreads [15] , and also when formulated in tablets [16] , but results have generally been variable. A meta-analysis of 19 human trials indicated however, that a combination of IPP and VPP induced an overall decrease in SBP of ∼4 mm Hg over a minimum of 8 weeks following doses of 2-10 mg peptide/day in a range of food products, a result that might be clinically significant [17] . Previously we have demonstrated that IPP and LKP are substrates for small intestinal epithelial cell uptake via the apical membrane-located intestinal Peptide Transporter 1, PepT1(SLC15A1) in vitro [18] , a high affinity pathway that can also be accessed by other food-derived peptides [19] [20] [21] [22] [23] . Involvement of PepT1 in mediating di-and tri-peptide transport is indicated by decreased small intestinal epithelial permeation in the presence of the PepT1 inhibitor, glycyl-sarcosine (Gly-Sar). PepT1 substrates typically have good oral bioavailability (e.g. valacyclovir, 50-70% [24] ), but there is potential for uptake to be inhibited by PepT1-competing pharmaceutical substrates or ones present in foodstuffs. For example, the fish muscle hydrolysate di-peptide derivative, Val-Tyr (VY), does not reduce blood pressure in SHRs to the same degree when co-administered with captopril due to competition for PepT1; both molecules were more efficacious in the absence of the other [25] . Similarly, the increased apparent permeability coefficient (P app ) of the PepT1 substrate, cephalexin, across isolated rat jejunal mucosae induced by Labrasol®, (comprising acylglycerol-and PEG esters of the medium chain fatty acids, sodium caprate (C 10 ) and sodium caprylate (C 8 )), was hindered in the presence of the PepT1 substrates, Gly-Leu and Ala-Ala [26] , suggesting competition for PepT1 between cephalexin and dipeptides.
The intestinal permeation enhancer, C 10 , is found in mM concentrations in milk [27] and also as a methyl ester ethoxylate in coconut oil and palm kernel oil [28, 29] . C 10 is well-known to increase oral absorption of large MW peptides and reached Phase II trials for an oral insulin as a component of Merrion Pharmaceutical's (Dublin, Ireland) GIPET™ solid dosage form [30] . Despite this, less studied is its potential to increase oral absorption of food-derived bioactives. In one example however, the poorly absorbed soy-derived isoflavone, diadzein, was entrapped in nanoparticles and co-administered with C 10 to rats, resulting in a 2-fold increase in plasma levels [31] . Previously, we reported that C 10 increased the permeation of fluorescein isothiocyanate (FITC)-labelled IPP and LKP by 1.4-3.6-fold respectively across isolated rat jejunal tissue mucosae [32] . The in vitro membrane perturbation mechanism that C 10 uses to increase paracellular permeability is due to a combination of elevation of intracellular Ca 2+ [33] , epithelial membrane fluidisation [34] , relocation of the tight junction-associated proteins, tricellulin and claudin 5 [35] , activation of phospholipase C [27] , and increased phosphorylation of myosin light chain kinase (MLCK) [36] . The hypothesis of this study was that C 10 might overcome a reduction in the in vitro and in vivo intestinal permeability of IPP and LKP in rats seen in the presence of Gly-Sar. Gly-Sar was used in an attempt to mimic the inhibition of PepT1 that may occur in the presence of peptides generated by lipases from food hydrolysates. First, the effects of Gly-Sar and C 10 co-administration on the permeability of ]-LKP absorption following oral gavage to normal rats over a short time frame and compared these data to the PD outputs. All in vitro and in vivo studies suggested that PepT1 plays a key role in the intestinal permeability of the tripeptides and that C 10 can overcome inhibition of flux by Gly-Sar. 
Materials and methods

Reagents and chemicals
where dQ/dt is the slope of the line (linearity required to be > 0.95 for inclusion), A is the surface area (1.12 cm 2 ) and C 0 is the starting concentration of flux marker on the apical side [37] . Basal TEER values were required to be > 1400 Ω·cm 2 in order for monolayers to be included for analysis [39] . Transport experiments were run in triplicate with three independent replicates.
Immunofluorescence of tight junction proteins in monolayers exposed to C 10
Confluent Caco-2 cells grown on 8 well Nunc™ Lab-Tek II chamber slides were exposed to C 10 (1.0 and 5.0 mM) in calcium-free HBSS for 120 min. Untreated control cells were incubated in HBSS. Following exposure, HBSS was removed and cells were washed gently with ice cold PBS. Cells were fixed in ice-cold methanol for 30 min and washed with PBS. Non-specific background was blocked by incubation with 5% bovine serum albumin in PBS overnight at 4°C. Cells were washed with PBS and permeabilized with 0.1% Triton™ X-100 in PBS for 10 min. Cells were probed with Alexa Fluor® 494 mouse monoclonal antibody against occludin (1:400), Alexa Fluor® 494 mouse monoclonal antibody against ZO-1 (1:400), and Alexa Fluor® 488 mouse monoclonal antibody against claudin-5 (1:400). The slides were washed with PBS and mounted in Dako fluorescence mounting media. Images were captured with an Axioplan Epi-fluorescence microscope (Zeiss, Germany).
Isolated rat jejunal mucosae transport studies in Ussing chambers
Rat studies were carried out in accordance with the UCD Animal Research Ethics Committee protocol (AREC 14-28-Brayden) and in adherence with European Union Directive 2010/63/EU in relation to the 3Rs and use of post mortem tissue. Male Wistar rats (250-350 g; Charles River Labs, UK, and the UCD Biomedical Facility) were euthanized by stunning and cervical dislocation. Jejunal mucosae with intact underlying circular and longitudinal muscle were mounted in Ussing chambers with a circular window areas of 0.63 cm 2 [40] . Mucosae were bathed apically with 5 ml calcium-free Krebs Henseleit buffer (KH), basolaterally with KH buffer, and both sides were continuously gassed with 95% CO 2 /5% O 2 with the temperature maintained at 37°C with a heated glass water jacket. The transepithelial potential difference (PD; mV) and short circuit current (I sc , µA·cm Jejunal mucosae transport experiments were carried out with a minimum of five independent replicates.
In vivo rat studies
All live animal procedures adhered to EU Directive 2010/63/EU and were performed in compliance with the Irish Health Products Regulatory Authority animal licence number AE18982/P037. Male Wistar rats (Charles River, UK) weighing 280-350 g and male SHRs (16-wk old, Charles River, Germany) weighing 260-320 g were used. Animals were housed under controlled environmental conditions regarding humidity and temperature with a 12:12 h light/dark cycle. Rats received filtered water and standard laboratory chow ad lib and were fasted for 16-20 h prior to procedure with free access to water. Animals were euthanized at the end of the experiment by an intra-cardiac injection of 0.4 ml pentobarbital sodium (EUTHATAL™, Merial Animal Health Ltd., UK).
PD studies in SHRs
Male SHRs (16-wk old, 260-320 g) with SBP over 170 mm Hg were randomised into test groups with 6 rats per treatment. Oral gavage and i.v. administration was carried out with captopril (5mg/kg both routes), and IPP and LKP (1 mg/kg and 5 mg/kg by i.v.; 10 mg/kg oral). Oral gavage was carried out using a curved 16 gauge needle to deliver 300 µl to the stomach. The effects of treatments on SBP were compared to that of PBS solution, the vehicle for all test agents. PepT1 inhibition studies compared responses following oral gavage to both IPP and LKP (both 5 mg/kg) in the presence of Gly-Sar (100 mM; 16 mg/kg), or in the presence of both Gly-Sar and C 10 (180 mM; 35 mg/kg). SBP was measured by tail-cuff plethysmography using the CODA® Mouse Rat Tail Cuff Blood Pressure System (Kent Scientific, U.S.A.) at 0, 1, 2, 3, 4, 6, and 8 h post administration after warming the rats in a chamber at 34°C for 5 min. Δ SBP changes were calculated by setting untreated basal readings to zero using GraphPad Prism-5® software. ]-LKP (8 µCi/kg; 8.9 mg/kg) were administered by gavage alone, in the presence of Gly-Sar (100 mM; 16 mg/kg), or in the presence of both Gly-Sar and C 10 (180 mM; 35 mg/kg). After oral gavage, the rats were anaesthetised with isoflurane (Iso-Vet, 1000 mg/g isoflurane liquid for inhalation, Piramal Healthcare, U.K.) at a rate of 4000 ml/min mixed with 4000 ml/min O 2 in an induction chamber. Anaesthesia was maintained with isoflurane 2500 ml/min mixed with 1500 ml/min O 2 using a delivery mask (Blease Medical Equipment Ltd., U.K.). Blood samples (∼400 µl) were taken via the retro-orbital route at selected time points up to 180 min into 1 ml Eppendorf tubes and stored on ice at 2-8°C prior to centrifugation (6500g, 5 min) and serum collection. 100 µl serum was mixed with 5 ml scintillation fluid (Ecoscint A scintillation cocktail) and concentrations were read in a Packard Tricarb 2900 TR scintillation counter.
Histology
Following the studies using isolated jejunal tissue in Ussing chambers and oral gavage studies in normotensive rats, jejunal mucosae were immersed in 10% (v/v) buffered formalin for 48 h. Tissues were prepared, paraffin-embedded, cut with a microtome, and dried overnight at 60°C. Tissues were stained with Alcian blue and neutral red. Slides were visualised under a light microscope (NanoZoomer 2.0-HT light microscopy, Hamamatsu) and images were taken with a high-resolution camera (Micropublisher 3.3 RTV, QImaging) and Image-Pro® Plus version 7.1 (Media Cybernetics Inc., USA) acquisition software.
Statistical testing of group comparisons and PK-PD analysis
Statistical analysis was carried out using GraphPad® Prism-5 software using one-way and two-way ANOVA with Dunnett's and Bonferroni's post hoc tests as appropriate. Results are presented as the mean ± standard deviation (SD). A significant difference was designated for all P values < 0.05 but without further denomination into multiple levels, as recently recommended by the Editors of the British Journal of Pharmacology [41] . The mean basal TEER for Caco-2 monolayers grown on Transwells® was 1984 ± 570 Ω·cm 2 (n = 48), within an acceptable range for differentiated monolayers for use in transport studies [39] . Apical addition of 10 mM Gly-Sar had no effect on TEER over 120 min, with values similar to those of untreated monolayers (Fig. 1A) . Apical addition of C 10 (1.0, 2.5, and 5.0 mM) decreased TEER to 49%, 31%, and 15% of basal values respectively over 120 min (Fig. 1A) . ). Apical addition of a low concentration of C 10 (1 mM) did not statistically increase the P app of either peptide in the absence of Gly-Sar, although there was a trend in the case of [ . Co-administration of Gly-Sar with 1 mM C 10 restored the P app values of both peptides to similar values seen in the absence of the inhibitor (Table 1) . When concentrations of C 10 were increased to 2.5 mM and 5 mM however, the P app values of both peptides were increased several fold over those seen in either the presence or absence of Gly-Sar.
Effect of C 10 on tight junction-associated proteins in Caco-2 monolayers
Apical addition of 1 mM C 10 for 120 min induced no overt perturbation or interference with the tight junction proteins probed (data not shown). Compared to untreated control monolayers however, 5 mM C 10 induced some cell sloughing and ZO-1 was internalised leaving poor membrane definition, indicative of membrane perturbation (Fig. 1B) . Claudin-5 and occludin were also relocated and internalised in the presence of 5 mM C 10 , suggestive of some loss of cell membrane integrity, likely accompanied by an increase in tight junction openings. This data indicates that increasing concentrations of C 10 led to reorganisation of TJ proteins and is consistent with the reciprocal reductions in TEER and increases in the P app of ). Apical addition of 10 mM C 10 had no effect on the P app values of either peptide alone. However in the presence of Gly-Sar, C 10 increased the P app of both peptides back up to basal levels ( Table 2) . When jejunal tissues were exposed to 20 and 30 mM C 10 , the P app increased for both peptides above the levels seen in either the presence or absence of Gly-Sar. Histological analysis of jejunal tissue was carried out following 120 min exposure to increasing concentrations of C 10 ( Fig. 2B) . Untreated tissue and tissue pre-incubated with Gly-Sar showed no major morphological changes. Apical addition of 10 mM C 10 however, induced cellular sloughing of the jejunal villi and increased mucus secretion after 120 min (Fig. 2B.iii) . Depth of villi perturbation and damage was more evident at the 20 mM and 30 mM C 10 concentrations. Overall, the jejunal structure was maintained and the crypts remained mostly unaffected in control tissues and exposed to Gly-Sar, but C 10 caused concentration-dependent damage at values > 10 mM, consistent with the TEER reductions.
Effects of Gly-Sar and C 10 on the anti-hypertensive action of the peptides in SHRs
The hypotensive effects of unlabelled IPP and LKP were assessed in SHRs by the i.v. (Fig. 3A) and oral gavage routes (Fig. 3B and C) . Captopril (5 mg/kg) statistically lowered SBP by both delivery routes Each value represents the mean ± SD, n = 3 independent replicates. B. Representative immuno-fluorescence analysis of selected tight junction proteins exposed to 5 mM C 10 for 120 min in Caco-2 monolayers grown on chamber slides. White arrows indicate areas of cell sloughing. Horizontal bars = 10 µm. For the further interpretation of reference to colour in the legend of (B), the reader is referred to the web version of this article. One-way ANOVA with Dunnett's multiple comparison. Mean ± SD, n = 3 independent replicates. * P < 0.05, C 10 ± Gly-Sar exposed monolayers compared with untreated control monolayers. a P < 0.05, for Gly-Sar exposed monolayers compared with untreated control monolayers.
compared to PBS, with no effects of PBS seen by both routes. Both IPP and LKP statistically decreased SBP by the i.v. route at 1 h and 2 h with doses of 1 mg/kg (P versus control, and also at each time point up to 6 h at a dose of 5 mg/kg IPP, and at time points up to 3 h only for 5 mg/kg LKP. 5 mg/kg captopril tended to be more effective than either peptide at later time points at the same dose level by the i.v. route, but this was not significant. Concerning oral administration of the two peptides and captopril to SHRs, there was a slower onset of hypotensive action compared to the i.v. route ( Fig. 3B and C) . Oral doses of 5 and 10 mg/kg of IPP and LKP induced a statistical reduction in SBP from 2 to 4 h with respect to PBS controls, whereas 1 mg/kg doses were ineffective. For the three dose levels of the peptides administered orally, there were dose-dependent blood pressure reductions for each. Captopril (5 mg/ kg) statistically reduced SBP at each time point up to 6 h and also at 8 h.
It was more efficacious then the two peptides following oral gavage at the 5 mg/kg dose level at the 6 h and 8 h time points. At these later time points there was no statistical reduction in SBP induced by the two peptides versus PBS in contrast to captopril. The effects of Gly-Sar and C 10 were then determined in relation to the hypotensive actions of IPP and LKP. Gly-Sar co-administration statistically inhibited the SBP decreases induced by IPP (Fig. 4A) and LKP (Fig. 4B ) at 120 min, however the inhibitory effects of Gly-Sar were partially reversed for both peptides to a statistical level in the presence of C 10 . The data suggest that the IPP-and LKP induced decrease in SBP in the presence of oral GlySar in SHRs could be partially reversed by C 10 .
Effects of C 10 and Gly-Sar on the serum levels of orally-gavaged [ 3 H]-IPP and [ 3 H]-LKP in normal rats
The effects of Gly-Sar and C 10 on the serum levels of [
H]-IPP and [
3 H]-LKP were determined over 180 min following oral gavage to normal rats (Fig. 5A) . A high concentration of 100 mM Gly-Sar was used in oral gavage studies instead of the 10 mM used in vitro in order to account for possible dilution in the GI tract [42] . In the presence of GlySar, there was a significant decrease in serum levels both For the further interpretation of references to colour in the legend of (B), the reader is referred to the web version of this article. One-way ANOVA with Dunnett's multiple comparison. Mean ± SD, n = 5 independent replicates. * P < 0.05, C 10 Gly-Sar exposed monolayers compared with untreated control mucosae. a P < 0.05, for Gly-Sar exposed mucosae compared with untreated control mucosae. When 180 mM C 10 [43] was co-administered with Gly-Sar and the peptides however, serum levels of [ 3 H]-IPP returned to 84% of levels attained in the absence of Gly-Sar, and that of [ 3 H]-LKP returned to 93%. Surprisingly, C 10 co-administration with the peptides was without effect on serum levels even at a high concentration of 180 mM; values were similar for both peptides in its presence and absence. Co-administration of C 10 therefore circumvented the reduction in peptide flux caused by Gly-Sar inhibition of the PepT1-mediated pathway, but C 10 had no effect on serum levels per se. This indicates that C 10 may reverse the inhibition of absorption of the two peptides by Gly-Sar in vivo. Histological analysis of jejunal tissue after oral gavage was carried out after exposure to treatments and showed no pathological damage from the rats dosed with Gly-Sar, C 10 , or the combination thereof (Fig. 5B ). There were no differences in histological damage, epithelial perturbation, cell sloughing, or increased mucus production between treated and untreated rats. It was notable that the jejunal histology from gavage studies in rats was in general better preserved than jejunal mucosae from Ussing chamber studies.
Discussion
The relatively high P app values [
3 H]-IPP and [
3 H]-LKP obtained across Caco-2 monolayers suggest that both molecules have higher permeability across the model than was anticipated for peptides. Examples of well-absorbed small molecules with a similar range of P app values across Caco-2 include (×10 −6 cm·s −1 ): atenolol, 2.2; talinolol, 1.8 [44] , and valacyclovir, 4.5 [45] , the latter being a substrate of PepT1. Furthermore, the Caco-2 P app values reported here are similar to the P app values of other short chain peptides determined across Caco-2: (×10 −6 cm·s −1 ): e.g. Ile-Phe, 2.4 [46] , Thr-Vap-Pro-Ser-Leu, 6.9 [20] , and Gly-Pro-His, 1.1 [22] , as well as Gly-Sar itself, 9.2 [44] . In addition, the P app values of ): oseltamivir, 4.6 [47] , captopril, 0.5 [25] , and cephalexin, 3.8 [26] . Foltz et al. [48] used LC-MS to assay permeated unlabelled IPP and reported P app values of 1.0 × 10
across Caco-2 monolayers and 9 × 10 −8 cm·s −1 across isolated rat jejunal mucosae, 100-fold lower than the values we report here for ]-LKP (black bars) following oral gavage co-administration of Gly-Sar (16 mg/kg; 100 mM) and C 10 (35 mg/kg; 180 mM) to normal rats. Each value represents the mean ± SD, n = 6 independent replicates. Statistical differences at the P < 0.05 level were noted in groups with horizontal capped lines for the respective peptide: Peptides + Gly-Sar groups are reduced compared to Peptides alone; the Peptides + Gly-Sar + C 10 groups are increased compared to the Peptides + Gly-Sar groups; Peptides + C 10 are increased over the Peptides + Gly-Sar groups. Peptides comprise IPP and LKP examined separately and statistics are for both peptides. (B) Alcian blue-and neutral red-stained representative light micrographs of jejunal tissue 180 min after oral gavage to normotensive rats: (i) Untreated (ii) 100 mM Gly-Sar, (iii) 180 mM C 10 , (iv) 100 mM Gly-Sar and 180 mM C 10 . Horizontal bars denote 100 µm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) tritiated IPP in each model. The discrepancy with our data is unlikely to be due to an artefact of tritium breaking off from the tripeptides during permeation for the following reasons: the radiolabel bond is covalentlylinked; the P app values of [ across three bioassays. Thus, although it is unlikely that detachment of the label occurred, this was not directly assessed by column chromatography or LC-MS. Similarly, while Caco-2 permeability values differ between laboratories may be are related to the clone source, differences in basal TEER, passage number, and serum lot, this does not explain the lack of similarity between the two studies for the rat jejunal P app data. Apical addition of C 10 in the presence of Gly-Sar increased the P app of both peptides to levels similar to those obtained in the absence of Gly-Sar in both Caco-2 monolayers and rat jejunal mucosae. It is known that C 10 fluidises the plasma membrane consistent with detergent-like perturbation [34] . Therefore, it is possible that the effect of C 10 on the apical membrane indirectly nullifies the effect of PepT1 inhibition by Gly-Sar. We speculate that C 10 allows the P app of the peptides to revert to basal levels by increasing their paracellular flux as a consequence of diverting them from the inhibited transcellular PepT1 pathway through initiating enzymatic and intracellular calcium-mediated events that modulate the tight junction [33] . PepT1-mediated uptake relies on H + -coupled co-transport, which is supported by an acid microclimate in the small intestine [49] . Alkalinisation of the microclimate can inhibit PepT1-mediated uptake [38] , and a lack of pH gradient will reduce the capacity for PepT1 to translocate substrates. The bile salt, sodium deoxycholate, is also a permeation enhancer, but it does not alter the pH of the microclimate in rat jejunum [50] , however we have not yet tested whether C 10 behaves similarly. Therefore in vitro, the evidence suggests that C 10 is acting predominantly by opening the paracellular route through indirect membrane-initiated intracellular mechanisms that lead to alterations in tight junction protein location and function. A model of this interpretation is presented (Fig. 6 ). In support of this interpretation, increasing concentrations of C 10 resulted in both a redistribution of TJ proteins in Caco-2 monolayers as well as causing cell sloughing from the tips of villi, as expected from a surfactant. C 10 has a long history of use in man and causes rapidly reversible membrane perturbations in more physiological-relevant models. Therefore the damage caused by C 10 in vitro is likely due to direct exposure to the intestinal epithelia for 120 min without the normal epithelial protective mechanisms available in vivo. Further studies in a larger animal model such as oral gavage in pigs would allow for dose-dependent assessment of the contribution of C 10 to the increase in plasma peptide levels. Unlike larger peptides, IPP and LKP have relatively low molecular weights (325 Da and 356 Da respectively) and are hydrophilic, thus making them suitable candidates for permeation via an enabled paracellular route in the event of PepT1 inhibition. Paracellular permeability typically requires a molecule to be < 500 Da and hydrophilic in order to pass tight junctions. As TJ proteins are transiently relocated and perturbed by permeation enhancers, tissue TEER reduces and the paracellular permeability of tracer molecules (e.g. FITC) increases across intestinal epithelia [51, 52] . However, concerns are often raised when the intestinal barrier is perturbed due to the possible translocation of bacteria, toxins, and bacterial lipopolysaccharide [53] . Previous studies with PEs have shown that the intestinal barrier repaired within 1-3 h [54] [55] [56] , and that the molecular diameter of molecules which can cross when the barrier is opened in a temporary fashion is quite low [52] . After co-administration of [ H]-LKP alone and this was consistent with the in vitro data. Restoring the oral absorption of a PepT1 substrate using an amphiphilic permeation enhancer, Labrasol®, was also previously reported in isolated rat jejunal mucosae for cephalexin [57] . Cephalexin permeability was reduced by 18% in the presence of Gly-Leu and Ala-Ala, but addition of Labrasol® restored permeability to basal levels. Similarly, oral absorption of oseltamivir, an antiviral prodrug and substrate for PepT1, was reduced when co-administered with either Gly-Sar or bovine milk in rats [58] . The authors argued that the inhibition of PepT1 by components of milk is due to intestinal hydrolysis of milk proteins leading to di-and tri-peptide competition for uptake via PepT1 of oseltamivir. On the other hand, a clinical trial showed an increase in oseltamivir plasma AUC 0-24h after administration with a high fat high calorie meal including milk compared to fasted state [42] . Perhaps the high fat content of the meal perturbed the intestinal epithelium, thereby acting in part as an emulsion-based permeation enhancer(s) to overcome the effect of PepT1 competition by the milk-derived peptides [59] . Furthermore, Matsui et al. reported that co-administration of VY with captopril nullified the individual hypotensive effect of both agents when administered to SHRs, and cautioned against simultaneous intake of ACE inhibitors and foods high in di-and tripeptides [25] . We note that there is some controversy over whether captopril is a true substrate for PepT1, as it has relatively weak affinity for PepT1 in transfected cells and there is speculation by the group of Brandsch that its high oral bioavailability may possibly be accounted for by passive diffusion or the influence of other transporters [60] . Nonetheless, the inhibition of flux of IPP and LKP by Gly-Sar across two in vitro bioassays, the inhibition of the blood-pressure lowering effects of the peptides in SHRs by Gly-Sar, along with a reduction in serum levels of the peptides by Gly-Sar in normal rats suggests that the two peptides are indeed substrates for PepT1.
The present study demonstrated that Gly-Sar co-administration partly reversed the hypotensive effect of both IPP and LKP in SHRs, but that addition of C 10 restored it. This is the first demonstration that a food-grade agent can enhance in vivo effects of bioactive peptides derived from food. Application of pharmaceutical technologies such as food-grade permeation enhancers and delivery systems to food bioactive peptides is an emerging area [61, 62] . Recently, Val-Leu-Pro-ValPro was encapsulated in a pol-(lactic-co-glycolic) acid-based nanoparticle, and exhibited sustained attenuation of hypertension compared to free peptide after oral administration to SHRs [63] . The European Food Safety Authority (EFSA) regulates health claims for foods, however both IPP and LKP were rejected due to lack of sufficient evidence of reducing blood pressure levels in the general population with foods enriched with IPP and LKP [64, 65] . However, it should be noted these peptides appear to be more effective in pre-hypertensive and hypertensive subjects compared to normotensive subjects [66] . Use of appropriate delivery systems may therefore yield a food-grade formulation to deliver an efficacious dose of these antihypertensive peptides to attenuate hypertension in pre-hypertensive subjects prior to the requirement for pharmaceutical intervention. ]-LKP in normal rats were reduced by ∼50% in the presence of GlySar in normal rats following oral gavage, suggesting involvement of PepT1 in the permeation pathway. C 10 was able to prevent the reduced serum levels of the peptides when co-administered with Gly-Sar, thereby returning values near to basal levels. C 10 may overcome PepT1 inhibition indirectly by enhancing paracellular permeability of IPP and LKP.
Conclusions
